問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Pediatrics

更新時間：2025-12-16

林谷龍
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林谷龍

List

7Cases

2018-01-01 - 2018-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2016-02-01 - 2016-12-31

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2015-12-01 - 2016-12-30

Phase III

A Multicenter, Randomized, Double-Blinded Comparative Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Daptomycin Versus Active Comparator in Pediatric Subjects with Acute Hematogenous Osteomyelitis Due to Gram-Positive Organisms

  • Condition/Disease

    Acute Hematogenous Osteomyelitis

  • Test Drug

    daptomycin (CUBICIN)

Participate Sites
5Sites

Terminated5Sites

2014-03-01 - 2016-03-31

Phase II

An Open-Label, Dose-Finding, Phase II Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Paediatric Subjects aged 3 to 6 years and 2 to 35 months old

  • Condition/Disease

    Prevention of Enterovirus 71 infection

  • Test Drug

    EV71 vaccine

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

黃高彬
China Medical University Hospital

Division of Pediatrics

2016-03-01 - 2018-10-31

Phase II

A phase II observer-blind, multicentre, dose-ranging study of children 6 to less than 36 months of age who are to be primed with a 2-dose series of GSK Biologicals’ AS03-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine

  • Condition/Disease

    Active immunization against influenza A virus H5N1 subtype

  • Test Drug

    GlaxoSmithKline (GSK) Biologicals’ Influenza A/Indonesia/05/2005 (H5N1) vaccine adjuvanted with AS03

Participate Sites
8Sites

Terminated7Sites

邱政洵
Linkou Chang Gung Medical Foundation

Division of Pediatrics

2016-05-01 - 2018-12-31

Phase II

A Randomised, Double-blind, Placebo-controlled, 2-Part Study of Orally Administered AK0529 to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Effect of Single and Multiple Dosing in Hospitalised Infants with Respiratory Syncytial Virus Infection

  • Condition/Disease

    Respiratory Syncytial Virus (RSV) Infection

  • Test Drug

    AK0529

Participate Sites
4Sites

Terminated4Sites

2014-09-01 - 2018-09-04

Phase III

A Phase III, Stratified, Randomized, Observer Blind, Controlled, Multicenter Clinical Study to Evaluate the Safety, Immunogenicity and Efficacy of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to NonAdjuvanted Comparator Influenza Vaccine in Children ≥6 to < 72 Months of Age.

  • Condition/Disease

    Vaccines to prevent influenza

  • Test Drug

    aQIV

Participate Sites
3Sites

Terminated2Sites

Study ended1Sites

黃高彬
China Medical University Hospital

Division of Pediatrics

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB